Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Descemet membrane endothelial keratoplasty versus descemet's stripping automated endothelial keratoplasty following glaucoma filtering surgery: clinical outcomes and immunologic considerations.

Created on 31 Jul 2026

Authors

Hirotsugu Kasamatsu, Shizuka Koh, Yukari Yagi-Yaguchi, Daisuke Tomida, Takefumi Yamaguchi

Published in

Japanese journal of ophthalmology. Jul 31, 2026. Epub Jul 31, 2026.

Abstract

To investigate the clinical outcomes and immunologic implications following Descemet membrane endothelial keratoplasty (DMEK) and Descemet's stripping automated endothelial keratoplasty (DSAEK) in eyes with prior glaucoma filtering surgery (GFS).
Retrospective comparative case series.
This study included 29 eyes with prior GFS that underwent DMEK (n=7) or DSAEK (n=22). Outcomes include host central corneal thickness (CCT), short-term complications (graft detachment, rebubbling, and primary graft failure [PGF]), corrected distance visual acuity (CDVA), immunologic graft rejection, endothelial cell loss (ECL), and graft survival.
DMEK showed significantly faster recovery of host CCT compared to DSAEK on postoperative day 1 (573.2 ± 93.3 μm vs. 773.0 ± 40.7 μm; p = 0.02) and day 3 (591.1 ± 93.2 μm vs. 721.5 ± 108.9 μm; p = 0.003). Graft detachment rates were similar between the groups; rebubbling and PGF occurred only after DSAEK (14% and 9%). CDVA at 1 month (0.5 ± 0.5 vs. 1.0 ± 0.5) and at 3 months (0.4 ± 0.4 vs. 0.8 ± 0.4) was significantly better in the DMEK group (both p = 0.04). The 2-year cumulative rejection rates (14% in both groups), 2-year ECL (70 ± 17% vs. 71 ± 15%), and 2-year graft survival rate (100% vs. 81 ± 10%) were comparable.
DMEK appears to be a viable option after GFS, given its favorable clinical profile. However, the relatively high incidence of immunologic events in both groups suggests that alterations in the ocular immune environment following GFS may influence postoperative outcomes.

PMID:
42536334
Bibliographic data and abstract were imported from PubMed on 31 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement